Alpha Tau Medical (DRTS) Non-Current Deferred Tax Liability (2025 - 2026)
Alpha Tau Medical (DRTS) posted Non-Current Deferred Tax Liability of $85000.0 for Q1 2026, down 12.37% sequentially from $97000.0 in Q4 2025.
Powered by 
Analysis
Alpha Tau Medical (DRTS) Non-Current Deferred Tax Liability (2025 - 2026) Analysis & Trends
Alpha Tau Medical has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $85000.0 in Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $85000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85000.0 (changed N/A YoY) and the FY2025 annual result came in at $97000.0, changed N/A from the prior year.
- Non-Current Deferred Tax Liability eased to $85000.0 in Q1 2026 per DRTS's latest filing, from $97000.0 in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $160000.0 in Q2 2025 and troughed at $85000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Alpha Tau Medical | 1.21 Bn | 1.11 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 312,000.00 |
| Mar 31, 2026 | 85,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 151,000.00 |
| Jun 30, 2025 | 160,000.00 |